AKT1 and autoimmune thrombocytopenic purpura: As proven by network pharmacology combined with experimental validation, by modulating signaling pathways such as PI3K-AKT and MAPK, the active components of SXXBC could promote megakaryocyte proliferation and differentiation, and ameliorate bleeding and immune phenotypes in ITP animal models [70].